Data sourcesSEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company
NTRANatera, Inc.
CIK 0001604821
Disclosed transactions60
Buys / sells0 / 60
Max Insider Score22
Connections20with evidence
NTRA · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 16 | RDRabinowitz DanielSEC. AND CHIEF LEGAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $134K 334 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
|
- Pharmaceuticals, devices & health servicesSEC SIC 8071 · Services-Medical Laboratories · Nov 4, 2026
- NATERA, INC. PAC (NATERA PAC)FEC Form 1 connected organization: NATERA, INC. (exact legal-name match) · Nov 4, 2026
- ERVIN GRAVES STRATEGY GROUP, LLCLDA RR 2026 first quarter · Health issues, Budget/appropriations, Defense, INS · Aug 26, 2026
- AKIN GUMP STRAUSS HAUER & FELD
13
MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS |
NTRANatera, Inc. Open-market sale · 10b5-1 plan |
| Nov 4, 2026 traded Nov 2, 2026 |
| 16 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $213K 520 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $166K 408 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $1,165 3 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $3,104 8 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $33K 80 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $50K 120 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $184K 470 sh | Nov 3, 2026 | Nov 4, 2026 traded Nov 3, 2026 | +1d | SEC FORM 4 | |
| 19 | RMRabinowitz MatthewDirector, EXECUTIVE CHAIRMAN | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $293K 731 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 19 | CLChapman Steven LeonardDirector, CEO AND PRESIDENT | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $366K 914 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $100K 240 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $127K 317 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | FJFesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $118K 295 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $49K 120 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $176K 432 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $81K 200 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 22 | CLChapman Steven LeonardDirector, CEO AND PRESIDENT | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $1.19M 2,866 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 19 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $316K 760 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $44K 109 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 16 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $164K 410 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | RMRabinowitz MatthewDirector, EXECUTIVE CHAIRMAN | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $6,599 17 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | FJFesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $2,717 7 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | CLChapman Steven LeonardDirector, CEO AND PRESIDENT | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $8,146 21 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | RDRabinowitz DanielSEC. AND CHIEF LEGAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $2,717 7 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $49K 120 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 19 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $369K 865 sh | Oct 28, 2026 | Oct 30, 2026 traded Oct 28, 2026 | +2d | SEC FORM 4 | |
| 16 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $133K 313 sh | Oct 28, 2026 | Oct 30, 2026 traded Oct 28, 2026 | +2d | SEC FORM 4 | |
| 19 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $811K 1,906 sh | Oct 30, 2026 | Oct 30, 2026 traded Oct 30, 2026 | +0d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $80K 187 sh | Oct 28, 2026 | Oct 29, 2026 traded Oct 28, 2026 | +1d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $118K 291 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 19 | RMRabinowitz MatthewDirector, EXECUTIVE CHAIRMAN | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $698K 1,718 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 19 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $511K 1,198 sh | Oct 28, 2026 | Oct 29, 2026 traded Oct 28, 2026 | +1d | SEC FORM 4 | |
| 19 | BBBrophy Michael BurkesCHIEF FINANCIAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $317K 781 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 22 | CLChapman Steven LeonardDirector, CEO AND PRESIDENT | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $1.46M 3,430 sh | Oct 28, 2026 | Oct 29, 2026 traded Oct 28, 2026 | +1d | SEC FORM 4 | |
| 19 | CLChapman Steven LeonardDirector, CEO AND PRESIDENT | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $919K 2,264 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 19 | RDRabinowitz DanielSEC. AND CHIEF LEGAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $413K 968 sh | Oct 28, 2026 | Oct 29, 2026 traded Oct 28, 2026 | +1d | SEC FORM 4 | |
| 19 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $495K 1,162 sh | Oct 28, 2026 | Oct 29, 2026 traded Oct 28, 2026 | +1d | SEC FORM 4 | |
| 19 | MSMoshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $410K 1,010 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 19 | FJFesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $383K 898 sh | Oct 28, 2026 | Oct 29, 2026 traded Oct 28, 2026 | +1d | SEC FORM 4 | |
| 19 | FJFesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $317K 781 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 19 | RDRabinowitz DanielSEC. AND CHIEF LEGAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $359K 884 sh | Oct 27, 2026 | Oct 29, 2026 traded Oct 27, 2026 | +2d | SEC FORM 4 | |
| 19 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $257K 627 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $87K 211 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $106K 255 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $52K 125 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $81K 200 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $69K 165 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 19 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $393K 962 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $249K 605 sh | Oct 21, 2026 | Oct 23, 2026 traded Oct 21, 2026 | +2d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $112K 280 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $33K 80 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $40K 98 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $32K 80 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $86K 215 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $14K 35 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $36K 90 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $24K 60 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $20K 50 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
| 16 | SJSheena JonathanDirector, CO-FOUNDER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $57K 142 sh | Oct 16, 2026 | Oct 20, 2026 traded Oct 16, 2026 | +4d | SEC FORM 4 | |
LDA Q1Y 2026 first quarter · issues not listed · Aug 26, 2026
THE CONSILIO GROUPLDA 1T 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026 Fesko JohnPRESIDENT, CHIEF BUS. OFFICER · Jan 16, 2026 NATERA, INC. PAC (NATERA PAC)